December 8, 2012Open Access
Apixaban for Extended Treatment of Venous Thromboembolism
Structured PICO
Does extended anticoagulation with apixaban reduce the risk of recurrent venous thromboembolism?
P
Population
Patients with venous thromboembolism requiring extended treatment
I
Intervention
Apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) for extended anticoagulation
O
Outcome
Recurrent venous thromboembolismhard clinical
Extended anticoagulation with apixaban (2.5 mg or 5 mg) effectively reduces recurrent VTE risk without increasing major bleeding.
Abstract
Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5 mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. (Funded by Bristol-Myers Squibb and Pfizer; AMPLIFY-EXT ClinicalTrials.gov number, NCT00633893.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
G
Giancarlo Agnelli
Vascular Medicine
Harry R. Büller
Vascular Medicine
A
Alexander T. Cohen
Vascular Medicine
Journals
New England Journal of Medicine
Actions
Institutions
McMaster University
Amsterdam UMC Location University of Amsterdam
Pfizer (United States)
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...